209 related articles for article (PubMed ID: 34307550)
1. Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma.
Hu X; Chen W
World J Clin Cases; 2021 Jul; 9(19):4998-5006. PubMed ID: 34307550
[TBL] [Abstract][Full Text] [Related]
2. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
3. Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents.
Khalafalla FG; Khan MW
Cancer Growth Metastasis; 2017; 10():1179064417709287. PubMed ID: 28579826
[TBL] [Abstract][Full Text] [Related]
4. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
5. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance.
Palamaris K; Felekouras E; Sakellariou S
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771695
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
7. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.
Satoh K; Hamada S; Shimosegawa T
J Gastroenterol; 2015 Feb; 50(2):140-6. PubMed ID: 25216997
[TBL] [Abstract][Full Text] [Related]
8. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
[TBL] [Abstract][Full Text] [Related]
9. The Role of
Racu ML; Lebrun L; Schiavo AA; Van Campenhout C; De Clercq S; Absil L; Minguijon Perez E; Maris C; Decaestecker C; Salmon I; D'Haene N
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205719
[TBL] [Abstract][Full Text] [Related]
10. Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link?
Karamitopoulou E
Front Oncol; 2013 Sep; 3():221. PubMed ID: 24062980
[TBL] [Abstract][Full Text] [Related]
11. The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion.
Yang J; Liu Y; Liu S
Cell Death Dis; 2023 Aug; 14(8):506. PubMed ID: 37550301
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Epithelial-Mesenchymal Transition and Metformin on Pancreatic Cancer Chemoresistance: A Pathway towards Individualized Therapy.
Gulla A; Andriusaityte U; Zdanys GT; Babonaite E; Strupas K; Kelly H
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454306
[TBL] [Abstract][Full Text] [Related]
13. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities.
Dardare J; Witz A; Merlin JL; Bochnakian A; Toussaint P; Gilson P; Harlé A
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451837
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma.
Jin KZ; Wu Y; Zheng XX; Li TJ; Liao ZY; Fei QL; Zhang HR; Shi SM; Sha X; Yu XJ; Chen W; Ye LY; Wu WD
FEBS J; 2023 Sep; 290(18):4577-4590. PubMed ID: 37245155
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
16. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
17. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
18. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
[TBL] [Abstract][Full Text] [Related]
19. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
20. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Li H; Jiang W; Liu XN; Yuan LY; Li TJ; Li S; Xu SS; Zhang WH; Gao HL; Han X; Wang WQ; Wu CT; Yu XJ; Xu HX; Liu L
Oncogene; 2020 Sep; 39(36):5825-5838. PubMed ID: 32753651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
